PARKINSON’S DISEASE INDUSTRY CLINICAL TRIALS REVIEW ANALYSIS 2017

Overview

Parkinson’s disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Parkinson’s Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Parkinson’s Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

 
Parkinson’s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555331-parkinson-s-disease-pipeline-review-h1-2017

 

Major Scope of the report:

– The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson’s Disease (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Parkinson’s Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
Table of Contents 

Table of Contents 2
Introduction 8
Parkinson’s Disease – Overview 9
Parkinson’s Disease – Therapeutics Development 10
Parkinson’s Disease – Therapeutics Assessment 50
Parkinson’s Disease – Companies Involved in Therapeutics Development 70
Parkinson’s Disease – Drug Profiles 154
Parkinson’s Disease – Dormant Projects 737
Parkinson’s Disease – Discontinued Products 751
Parkinson’s Disease – Product Development Milestones 753
Appendix 765

List of Tables
Number of Products under Development for Parkinson’s Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555331-parkinson-s-disease-pipeline-review-h1-2017

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.